Minerva Surgical Inc
NASDAQ:UTRS
Intrinsic Value
Minerva Surgical, Inc. is a medical technology company, which engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. [ Read More ]
The intrinsic value of one
UTRS
stock under the Base Case scenario is
6.366
USD.
Compared to the current market price of 0.001 USD,
Minerva Surgical Inc
is
Undervalued by 100%.
UTRS's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
UTRS or that its price is influenced by factors unrelated to fundamentals.
Minerva Surgical Inc's market capitalization is 23.9k USD.
UTRS stock price is 0.001 USD.
UTRS stock price (0.001 USD) is 100% less than its Intrinsic Value (6.366 USD).
UTRS. Open DCF Valuation
UTRS stock price (0.001 USD) is 100% less than its Relative Value (6.366 USD). Open Relative Valuation
UTRS has upside potential of 299 900% compared to the average analyst price target.
Open Wall St Estimates
UTRS's Revenue has grown by 3% over the past 12 months.
UTRS's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
UTRS's D/E (Debt to Equity) is equal to 1.37.
UTRS's long-term assets (73m USD) exceed its long-term liabilties (53m USD).
UTRS has positive Net Debt. This means that the company has more debt (28m USD) than cash and short-term investments (11m USD).
UTRS's short-term assets (40m USD) exceed its short-term liabilties (21m USD).
UTRS has negative Operating Income for the last twelve months.
UTRS has negative Net Income for the last twelve months.
UTRS's ROE (Return on Equity) for the past 12 months is negative and is equal to -160%.
UTRS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -47%.
UTRS has positive Gross Profit for the last twelve months.
UTRS has negative Free Cash Flow for the last twelve months.
UTRS has negative three-year average ROE (Return on Equity): -63%. The company is not efficient at transforming stockholders' equity into net income.
UTRS has negative three-year average ROIC (Return on Invested Capital): -49%. The company is not efficient at using invested capital to generate operating income.
UTRS's Altman Z-Score is very low and is equal to -5.57.
UTRS doesn't generate enough operating income (-29m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
Minerva Surgical Inc
Balance Sheet Decomposition
Minerva Surgical Inc
| Current Assets | 40m |
| Cash & Short-Term Investments | 11.1m |
| Receivables | 7.6m |
| Other Current Assets | 21.3m |
| Non-Current Assets | 32.8m |
| PP&E | 9.4m |
| Intangibles | 22.3m |
| Other Non-Current Assets | 1.1m |
| Current Liabilities | 21.3m |
| Accounts Payable | 3m |
| Accrued Liabilities | 6.4m |
| Other Current Liabilities | 11.9m |
| Non-Current Liabilities | 31.2m |
| Long-Term Debt | 27.9m |
| Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
Minerva Surgical Inc
|
Revenue
|
51.7m
USD
|
|
Cost of Revenue
|
-23.7m
USD
|
|
Gross Profit
|
28m
USD
|
|
Operating Expenses
|
-57.3m
USD
|
|
Operating Income
|
-29.3m
USD
|
|
Other Expenses
|
-4.2m
USD
|
|
Net Income
|
-33.5m
USD
|
Free Cash Flow Analysis
Minerva Surgical Inc
UTRS Profitability Score
Profitability Due Diligence
Minerva Surgical Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Minerva Surgical Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
UTRS Solvency Score
Solvency Due Diligence
Minerva Surgical Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Minerva Surgical Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UTRS Price Targets Summary
Minerva Surgical Inc
Ownership
UTRS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
UTRS Price
Minerva Surgical Inc
| Average Annual Return | -69.97% |
| Standard Deviation of Annual Returns | 36.26% |
| Max Drawdown | -100% |
| Market Capitalization | 23.9k USD |
| Shares Outstanding | 23 891 452 |
| Percentage of Shares Shorted | 3.7% |
Company Profile
Minerva Surgical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Minerva Surgical, Inc. is a medical technology company, which engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Santa Clara, California and currently employs 157 full-time employees. The company went IPO on 2021-10-22. The firm has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of abnormal uterine bleeding (AUB) in most uterine anatomies. Its solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The firm offers a suite of products for the treatment of structural and non-structural causes of AUB in most uterine anatomies. Its devices are utilized by obstetrician-gynecologists (OB/GYNs) across a variety of medical treatment settings, including hospitals, ambulatory surgical centers (ASCs) and physician offices.
You don't have any saved screeners yet
